Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice

PLoS Currents

Volumn , Issue AUG, 2009, Pages 1-4

  Dormitzer, Philip R ^a   Rappuoli, Rino ^b   Casini, Daniele ^c   O'Hagan, Derek ^d   Runham, Celene ^b   Montomoli, Emanuele ^f   Baudner, Barbara ^c   Donnelly, John J ^e   Lapini, Giulia ^g   Wack, Andreas ^g  

^a Vaccines Research   (United States)

^b Novartis Vaccines and Diagnostic   (United States)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d Novartis Vaccines Global Engineering   (United States)

^e UNIVERSITY OF SIENA   (Italy)

^f Novartis   (Italy)

^g NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873440380     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1025     Document Type: Article

References (8)

1. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009 Jul 10;325(5937):197-201. Epub 2009 May 22. PubMed PMID: 19465683.
2. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):521-4. PubMed PMID: 19478718.
3. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007 Oct;6(5):699-710. Review. PubMed PMID: 17931151.
4. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63-73. Review. PubMed PMID: 15088777.
5. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7. Epub 2009 Apr 27. PubMed PMID: 19416838; PubMed Central PMCID: PMC2674105.
6. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine. 2003 Apr 2;21(15):1687-93. PubMed PMID: 12639491.
7. Dolin R, Wise TG, Mazur MH, Tuazon CU, Ennis FA. Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. J Infect Dis. 1977 Dec;136 Suppl:S435-42. PubMed PMID: 342618.
8. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec. 2009 Jun 19;84(25):249-57. English, French. PubMed PMID: 19537358.